GlassScriptPhysician profile
Erika H Poehm
NPI 1669448551
$567.50
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.58 · 2021: $53.30 · 2022: $483 · 2023: $15.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $96.68 | 2022 | |
| Ucb, INC. | $90.84 | 2022 | |
| Biogen, INC. | $71.22 | 2022 | |
| Alexion Pharmaceuticals, INC. | $67.90 | 2022 | |
| Abbvie INC. | $62.69 | 2022-2023 | |
| Janssen Biotech, INC. | $38.00 | 2022 | |
| Adamas Pharmaceuticals, INC. | $16.58 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $16.50 | 2022 | |
| Urovant Sciences INC | $14.33 | 2022 | |
| Acadia Pharmaceuticals INC | $14.01 | 2021 | |
| Amgen INC. | $13.93 | 2022 | |
| Jazz Pharmaceuticals INC. | $13.82 | 2021 | |
| Lilly USA, LLC | $13.23 | 2022 | |
| Novo Nordisk INC | $12.81 | 2021 | |
| Mylan Specialty L.P. | $12.66 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $12.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erika Poehm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.